Announcements
- PHAXIAM provides Business and Financial Update for the First Quarter of 2024
- PHAXIAM Therapeutics fait le point sur ses activités et publie l’information financière du premier trimestre 2024
- Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 30 avril 2024
- Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2024
- PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
- PHAXIAM Therapeutics annonce le recrutement du premier patient dans l’étude de phase 1 dans l’endocardite infectieuse causée par le Staphylococcus aureus
- Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024
- Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 mars 2024
- PHAXIAM Therapeutics annonce le dépôt de son Document d’Enregistrement Universel (URD) 2023
- PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)
More ▼
Key statistics
On Friday, Phaxiam Therapeutics SA (2E40:BER) closed at 3.06, 7.76% above its 52-week low of 2.84, set on Mar 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.08 |
---|---|
High | 3.08 |
Low | 3.02 |
Bid | 2.84 |
Offer | 3.27 |
Previous close | 3.08 |
Average volume | 0.00 |
---|---|
Shares outstanding | 6.08m |
Free float | 5.60m |
P/E (TTM) | -- |
Market cap | 18.53m EUR |
EPS (TTM) | -5.56 EUR |
Data delayed at least 15 minutes, as of May 24 2024 20:50 BST.
More ▼